The ARHGAP10 Knockout HT29 Polyclonal Cells constitute a CRISPR/Cas9-mediated polyclonal knockout population derived from the HT29 human colorectal adenocarcinoma line, designed for disruption of the ARHGAP10 gene to enable functional studies of this tumor suppressor in colorectal cancer.
The HT29 parental cell line was originally isolated from a primary colorectal adenocarcinoma of a 44-year-old female and displays an adherent epithelial morphology. It harbors inactivating mutations in the tumor suppressors APC and TP53, an activating KRAS mutation, and a near-triploid karyotype. HT29 cells can differentiate in culture to form polarized monolayers with mucus-secreting enterocyte-like properties, making them a widely used model for intestinal epithelial barrier function and colorectal cancer biology.
ARHGAP10 encodes a Rho GTPase-activating protein that accelerates GTP hydrolysis on the small GTPases RhoA, Cdc42, and Rac1, thereby converting them to inactive GDP-bound conformations. This activity suppresses downstream effectors including ROCK and PAK1, leading to reduced LIMK-mediated phosphorylation of cofilin, which promotes actin depolymerization and inhibits stress fiber assembly and focal adhesion maturation. ARHGAP10 is itself regulated by upstream focal adhesion kinase (PTK2/FAK), SRC family kinases, integrin-mediated adhesion, and growth factor receptors, and it physically interacts with vinculin and paxillin at adhesion complexes. By negatively controlling Rho GTPase signaling, ARHGAP10 functions as a tumor suppressor that limits actin cytoskeletal reorganization, cell adhesion turnover, migration, and proliferation.
In the HT29 background, which already carries oncogenic mutations in KRAS and loss-of-function alterations in APC and TP53, disruption of ARHGAP10 removes a critical inhibitory constraint on Rho GTPase pathways. The resulting hyperactivation of RhoA, Cdc42, and Rac1 in this polyclonal knockout population leads to enhanced stress fiber formation, increased focal adhesion dynamics, elevated cell migration, and altered proliferation, thereby modeling cooperative tumor progression mechanisms in colorectal cancer.
This polyclonal ARHGAP10 knockout model is well-suited for a variety of applications in cancer biology and signal transduction research, including the study of Rho GTPase signaling mechanisms in colorectal cancer, investigation of cytoskeletal regulation in intestinal epithelial cells, and functional analysis of ARHGAP10 as a tumor suppressor. It supports drug discovery efforts for anti-metastatic target validation and high-throughput screening of small-molecule modulators of the actin cytoskeleton. Researchers can assess Rho GTPase activation using GST-RBD/PDB pull-down assays, visualize dynamic changes in actin and focal adhesion markers by immunofluorescence, quantify cell migration via transwell and scratch wound healing assays, evaluate proliferation, and monitor signaling node phosphorylation such as FAK Tyr397 by western blotting. The polyclonal nature of the population enables examination of heterogeneous gene-disruption effects within an isogenic background. For further details and technical support, please contact Ascent Research.
